T he corneal limbal epithelium is located at the transitional zone between the cornea and the bulbar conjunctiva. The limbal epithelial stem cells contained in the basal layer ensure the renewal of the corneal epithelium and serve as a barrier between the corneal and conjunctival epithelia. [1] [2] [3] Injury to the corneal limbal epithelium, resulting from severe exogenous trauma such as thermal burns, chemical injuries, or endogenous eye disease, may cause partial or total limbal stem cell deficiency (LSCD). 4 -6 Total LSCD is a dysfunction or destruction of the entire limbal epithelial stem cell population, resulting in the progressive destruction of the corneal epithelium. 7 LSCD is characterized by conjunctival epithelial ingrowth, neovascularization, chronic inflammation, opacification, recurrent corneal erosion and persistent ulcers, the destruction of basement membrane components, and fibrous tissue ingrowth. It leads to functional impairment such as discomfort, chronic pain, photophobia, and dry eye, and may ultimately lead to visual impairment and even blindness. 2,8 -10 Autologous limbal graft (for application either directly or after ex vivo expansion) cannot be used in cases in which there has been bilateral damage to the patient's ocular surfaces by injury or disease. The alternative treatment is the transplantation of allogenic limbal epithelium in the form of a keratolimbal allograft from cadaveric tissue or a living HLA-matched donor. [11] [12] [13] [14] Allogenous limbal graft is not regarded as a standard treatment, 11 since it requires systemic immunosuppression and has a success rate that tends to decrease gradually over time (graft survival rate of 40% at 1 year and 33% at 2 years). 15 Treatment with autologous oral mucosa grafted onto ocular surfaces 16 is considered to be safe, despite the risk of contamination. However, it is not effective in improving vision, probably because it contains opaque subepithelial fibrous tissue and it has a heterogeneous thickness.
The CAOMECS is manufactured by using a novel temperature-responsive culture well, UpCell-Insert (CellSeed, Inc., Tokyo, Japan), 17 and is harvested without proteolytic processing, retaining cell-to-cell junctions as well as the deposited extracellular matrix of the basal membrane of the sheet. 18 -20 Moreover, it makes it possible to transplant the sheet with no support or substrates, which may cause opacity. Thus, the cell sheet is transparent, resistant, viable, and rapidly bioadhesive, which means it can be grafted onto the corneal stroma without suturing. CAOMECS transplantation is proposed for the treatment of patients with total bilateral LSCD with moderate or severe symptoms, for whom any other treatments are not applicable. The efficacy of CAOMECS transplantation has been suggested by the presence of epithelium replacement, both in nonclinical studies using rabbit LSCD models 18, 19 and in a clinical study including four patients with total bilateral LSCD with severe loss of vision (Ͻ1/10) in Japan. 20 However, it was not possible to make a precise analysis of the risks and benefits from this preliminary study.
We performed a clinical trial to confirm the safety and efficacy of CAOMECS with a prospective, noncomparative, two-stage Gehan design.
MATERIAL AND METHODS

Design
This prospective, noncomparative and single institution study was designed according to the Gehan two-stage protocol. 21 The lowest limit of therapeutic activity considered to be of clinical importance was chosen as 30%, and the selected rejection error was 10%. In accordance with Gehan's two-stage design, seven patients were included in the first stage.
The number of success 3 months after grafting during the preliminary phase was used to determine the number of patients needed for the follow-up phase (16 -18 , according to our initial hypothesis).
Patients
The research adhered to the Declaration of Helsinki. Patients gave written informed consent before entering the study, which was approved by the local ethics committee. Patients 18 years of age or older were eligible for the study if they had total bilateral LSCD diagnosed by the same ophthalmologist with a slit lamp examination, as having a complete disappearance of the palisades of Vogt in the limbal area and a pathologic corneal epithelium, 22 with persistent defects, recurrent ulcers, chronic keratitis with scarring and punctate epithelial keratitis (PEK), and neovascularization with conjunctival invasion. Only one eye in each patient (the most severely affected) was grafted with a CAOMECS.
Patients were not included if they presented with one of the following: acute systemic infection, history of an acute phase of ocular inflammation in the previous year, history of neoplastic disease, glaucoma (diagnosed by measuring intraocular pressure with air or applanation tonometer), total symblepharon (comprising eyelid aperture), a history of hypersensibility or allergy to antibiotics or serum, pregnancy, or infectious disease.
Treatment Procedure
Harvesting and Culture of Oral Mucosal Epithelial Cells. After sterilization of the oral cavity and local anesthesia, a 3 ϫ 3-mm oral mucosa biopsy was excised from the cheek for epithelial cell culture as previously described. 23 After enzymatic treatment, the cells were seeded on UpCell-Inserts (CellSeed, Inc.), placed in a sixwell plate containing mitomycin C (MMC)-inactivated 3T3 fibroblasts as feeder layers, and cultured at least 4 days after confluence. Before grafting, the sheet was detached by reducing the temperature to Ͻ30°C and transferred to a PVDF ring.
The risk of viral contamination was assessed by testing with a microbial detection system (BacT/Alert; bioMerieux, Marcy l'Etoile, France) on different media for HIV1 and -2, hepatitis B and C, herpes virus types 1 and 2, herpes virus and Mycoplasma, and sterility.
The characterization of epithelial cells was performed as previously described 22, 23 using the K3/76 marker (anti-AE5 monoclonal antibody staining; Progen Biotechnik, Heidelberg, Germany). The presence of progenitor cells was tested for using anti-p63 (BD Pharmingen, Le Pont de Claix, France) and anti-␤1-integrin (Santa Cruz, Heidelberg, Germany) stainings. All staining was performed using both immunocytology on parallel cell culture and immunohistology on the CAOMECS. The presence of a basement membrane was assessed with anti-laminin 5 staining (Millipore, Molsheim, France) on the CAOMECS.
To assess colony forming efficiency (CFE), 20 or 40 cells/cm 2 were seeded on MMC-inactivated feeder layers. After cultivation for 12 days under the same conditions, CFE was determined as the ratio of the number of cells that produced large regular clones containing putative epithelial stem versus total seeded cells. Transplantation of the Cell Sheets onto the Eye. The conjunctival and subconjunctival scar tissue and all residual epithelium were removed from the patient's cornea up to 3 mm outside of the limbus, to re-expose the corneal stroma. After electrocoagulation was performed on all limbal vessels and the stroma was dried, the harvested CAOMECS was placed directly onto the exposed stromal bed (the total diameter of the graft was 20 mm). No sutures were required since the presence of basement membrane ensured immediate adhesion. The grafted corneal surface was immediately covered with a soft contact lens (Night and Day; Ciba Vision, Duluth, MN) to protect the CAOMECS during the first days. After surgery, topical antibiotics (0.3% ofloxacin) and corticosteroids (0.1% betamethasone) were initially applied four times a day and then three times a day. During the first week after surgery, betamethasone (4 mg per day) was administered orally to reduce postoperative inflammation. One month after surgery, the administration of topical corticosteroids was changed from 0.1% betamethasone to 0.1% fluorometholone. Since most patients had severe dry eye (due to defective tear production), preservative-free artificial tears were used at each patient's discretion throughout the study period. In cases of symblepharon, fornix reconstruction was always performed in patients before transplantation.
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Trial Outcomes
The primary endpoint for efficacy was measured at 360 days after grafting using the following criteria (the normal condition is italicized and underlined) by the same ophthalmologist (who was also the performing surgeon) through a direct observation using the slit lamp examination with and without fluorescein test:
Epithelial defect: no ulcer or mild (ulcer diameter Ͻ5 mm), moderate (diameter between 5 and 7 mm), or severe (diameter Ͼ7 mm) ulcer PEK: mild, moderate, or severe Conjunctival epithelium on cornea: absence or presence Corneal vascularization: number of vascular pediculi (stem vessel branching out from the limbus) Corneal vascularization, vessel activity: inactive (absence of blood), small-diameter vessels, different-diameter vessels, large-diameter vessels, and vasodilated vessels
The treatment for a patient was considered to be a success if all five criteria either improved or remained stable if normal at inclusion. The treatment was regarded as a failure if at least one criterion worsened or if one criterion that was subnormal at inclusion remained stable.
The secondary endpoints were the patient's functional signs assessment (by interview with the ophthalmologist) covering photophobia (no complaint, fear of luminosity corrected by sunglasses, frequent winking to light, and inability to open the eye), watering (no complaint, dry, very dry, and difficulty opening the eye), and pain (no complaint, occasionally, repetitive pain during the day, and permanent); the assessment of clinical efficacy based on physical signs at the slit lamp examination (corneal opacification from clear to severe dense opacity); and evaluation of visual acuity according to the ability to see hand motion (at 20, 50, and 100 cm), ability to count fingers (at 20, 50, and 100 cm), and Snellen's scale (Ͻ1/20, 1/20, 1/10, and 10/10).
Safety was assessed by documenting ocular adverse events that occurred during the patients' follow-up.
Follow-up
Patients were followed up for 1 year after the CAOMECS graft, with seven medical visits scheduled: after surgery and 15, 30, 60, 90, 180 and 360 days after transplantation.
Statistics
Two populations were defined. The safety population was defined as all patients receiving the graft. The efficacy population was defined as all patients with the evaluation criterion available at 360 days; patients with serious adverse events (SAEs) were recorded as having failed grafts. The analysis was descriptive. The success rate is presented with the corresponding 95% score confidence interval. 25 
RESULTS
A total of 25 patients were initially included, one patient was lost to follow-up after 30 days and was replaced, giving a total of 26 registered and treated patients (26 eyes were treated, but one patient was included twice, because he was treated in one eye and subsequently in the other eye). All patients received the CAOMECS graft between October 29, 2007 , and June 29, 2009 . The median age of the patients included in the study was 52 years. The other characteristics and medical histories of the patients are presented in Table 1 . Two patients had simultaneous CAOMECS and corneal stromal grafts.
Characterization of Tissue-Engineered Epithelial Cell Sheets
Transplantable and transparent oral mucosal cell sheets (Fig. 1A) were produced after culturing the patient's oral mucosal cells for approximately 3 weeks. Expressions of K3/76 were observed in the cells (Fig. 1 C1) and cell sheets (Fig. 1C2 ) of all patients. These data suggest that all transplanted cell sheets derived from oral mucosal epithelial cells showed similar morphologic characteristics to normal corneal epithelium.
The expression of p63 and ␤1-integrin as markers of putative epithelial stem cells (Figs. D1, D2 , E) as well as the CFE of 3.4% Ϯ 2.06% with the presence of holoclones (Fig. 1B) demonstrate the presence of putative stem cells.
The extracellular expression of laminin 5 verified the preservation of the extracellular matrix component of the basal membrane (Fig. 1F ).
Safety
Overall, seven patients had ocular adverse events ( Table 2) . Two of these events were serious. The first SAE was related to an inflammatory event. One month after the CAOMECS graft, inflammation persisted and neovascularization appeared. This patient presented a corneal perforation at 7 months after grafting. However, this event was due to the removal of the conjunctival and subconjunctival scar tissue and was therefore classified as "not related to the experimental product. " Moreover, the untreated eye also presented with perforation. The second SAE occurred in a patient who experienced a massive stroma graft rejection 4.5 months after the simultaneous transplantation of CAOMECS and corneal stromal grafts (the immunosuppressive treatment consisted of local corticosteroids). An ulcer over the whole donor corneal graft surface with strong vascularization required amniotic membrane surgery.
The adverse events in the other five patients were due to hypoxia from wearing contact lenses for too long or an inflammatory reaction. For two patients, it was also due to an associated pathology: hypertension caused by corticosteroid treatment resulting in glaucoma in one case and optical nerve atrophy in the other.
Efficacy
Intermediate Analysis. According to Gehan's design, an intermediate analysis was performed at 3 months after grafting for the first seven graft recipients ( Table 3) .
The results of the intermediate analysis rejected the inefficacy of the treatment with CAOMECS, with four successes observed. The patients were observed for a further 9 months, and, in line with Gehan's method, 18 more patients were included in the study and followed for 1 year.
Final Analysis. Twenty-five patients were evaluated for the main criteria (Table 3 ). The two patients who experienced SAEs were not assessed at 360 days after grafting, and their grafts were regarded as failures. The trial outcome at 360 days after grafting was regarded as a success in 16 (75%) of 25 patients (score 95%CI, 45-80). The grafts in the two patients with simultaneous grafting were failures. When considering the 23 patients assessed at 360 days after grafting, the number of improved patients was 19 for PEK (example in Figs. 2C, D) , 22 for the number of vascular pediculi, and 20 for vessel activity. Concerning persistent epithelial defect, 11 patients of the 12 with ulcers at inclusion were improved (example in Figs. 2A, B) . Eleven patients of the 15 with conjunctival epithelium on the cornea at inclusion were improved. The evolution of corneal vascularization is shown in Figure 3 (before grafting, A, C, E, and after, B, D, F).
Regarding the secondary evaluation criteria, the two patients who experienced SAEs were not assessed at 360 days after grafting; therefore, the following results include 23 patients.
Concerning photophobia, watering, and pain, 22 patients showed improvements in at least one criterion, and 7 showed improvements on all three criteria (Table 4) . Seventeen patients improved in visual acuity (Table 4) .
Concerning corneal opacification, 12 patients had moderately dense opacity partially obscuring details of the iris at inclusion: 9 remained stable and 3 moderated (decrease in the initial opacity); 9 had mild opacity (2 worsened and 7 remained stable), 1 had Colors show the severity of the results, with green being the least and red being the most severe:
. * Mild, ulcer diameter <5 mm; moderate, diameter between 5 and 7 mm; severe, diameter >7 mm.
severe dense opacity that moderated and the last patient had a clear cornea or a trace of haze and remained stable.
DISCUSSION
In this study, the CAOMECS was regarded as a success based on a composite criterion in 16 (64%) of 25 patients assessed at 360 days after grafting. We also found that 22 of the 23 patients experienced improvements in photophobia, watering, or pain and that visual acuity improved in 17. The CAOMECS was also safe; two SAEs occurred but were not related to the product. In 5 of 23 patients, there was reconstruction of the corneal epithelium without ulcers or neovessels. Our results demonstrate that the CAOMECS can restore cornea epithelial function while repressing neovascularization and conjunctivalization and improving visual acuity in cases in which the stroma was sufficiently healthy. For the patients whose stromas were heavily damaged, the CAOMECS transplantation reduced the neovascularization process.
Concerning vascularization, the expected invasion by active vessels initially eliminated by limbal electrocoagulation did not occur. After 1 year, there was a notable decrease in neovessels in the corneas of all patients, although in nine patients there was a partial recurrence of neovessels on a localized part of the cornea where there was no apparent loss of the CAOMECS. The reason has not been identified at this stage; however, it could be hypoxia (wearing extended-wear contact lenses for excessive lengths of time), high levels of dryness, and/or poor quality of the stromal bed. Previous studies on oral mucosal epithelial sheet transplantation also indicated the partial recurrence of neovessels. 20, 26 Thus, the biological activity of the oral epithelial sheet intended to inhibit neovascularization may be somewhat less effective than in real corneal epithelium. The lacrimal problem required most patients to use artificial tears.
The new temperature-responsive UpCell-Insert technology (CellSeed, Inc.) 27 makes it possible to harvest CAOMECS without enzymatic treatment, preserving cell-cell junctions and the basement membrane component, such as laminin 5, and giving rise to a cohesive sheet that can be prepared without a carrier, such as fibrin gel and amniotic membranes. Basal membrane protein preservation verified by the laminin 5 extracellular deposition allows for easy transplantation without suturing (in contrast with other culture techniques), and immediate adhesion between the CAOMECS and stroma. 20 The absence of suturing is the most innovative part of this technique. Sutures are known to induce pain, discomfort, and inflammation and to have an impact on the patient's quality of life. In this study, we found that the criteria regarding patient comfort improved after the graft.
Considering that all grafts had at least a 1-year follow-up and knowing that the lifespan of transient amplifying cells is believed to be less than 1 year, 28 we suggest that CAOMECS contains stem cells, as demonstrated by the CFE at 3.4%. These putative stem cells ensure the constant renewal of corneal epithelium after CAOMECS transplantation, required to avoid conjunctivalization and neovascularization.
The main limitation of this study is the absence of a control group. However, Gehan's two-stage design was adapted to this particular case in which the patients did not have any alternative therapeutic solution and in which no natural positive evolution was expected. We chose to select patients according to etiology and length of evolution (selection of pathologies known to destroy limbal epithelium) and confirmed by a clinical and slit lamp examination. We did not perform impression cytology to ascertain total LSCD, since it had not been approved by the time the study was initiated. Indeed, at the beginning of the clinical trial commonly used markers had no sufficient predictive value: for instance, the detection of conjunctival goblet cells using conventional cell cytology collected by means of impression cytology of the corneal epithelium 4, 8 did not seem to us a good diagnostic criterion, given the high variability in the density of goblet cells, which may even disappear from the ocular surface for certain LSCD etiologies. 29 -32 The fact that the main outcome was measured by a single ophthalmologist who was not masked could be regarded as a weakness of the study. However, the clinical signs were evaluated by one of the few French specialists in the cornea and LSCD disease, thus ensuring good grading quality.
In conclusion, we demonstrated that CAOMECS is a welltolerated and safe tissue-engineered product for the treatment of human LSCD. CAOMECS reconstructed the patients' ocular surface (i.e., new epithelium and less vascularization or less vessel activity), resulting in better visual acuity in cases of healthy stroma. CAOMECS should also be beneficial in patients with total bilateral LSCD, whose corneal stroma is severely damaged and cannot receive a secondary graft (donor cornea) due to the presence of neovessels, which would hinder its success. A decrease in the rejection risk for a secondary donor cornea graft is expected in recipients of a CAOMECS transplantation after 1 year. This was the case in 11 patients, who are currently in follow-up for assessment.
